Results 41 to 50 of about 3,442,924 (154)

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. [PDF]

PLoS One, 2020
Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor.
Nair S, Trummell HQ, Rajbhandari R, Thudi NK, Nozell SE, Warram JM, Willey CD, Yang ES, Placzek WJ, Bonner JA, Bredel M.   +10 more
europepmc   +2 more sources

Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. [PDF]

J Cancer Res Clin Oncol, 2022
Kim SA, Park H, Kim KJ, Kim JW, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW.   +17 more
europepmc   +2 more sources

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Frontiers in Oncology, 2021
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem.
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Patrick Pauwels, Marc Peeters, Marc Peeters, Jan Baptist Vermorken, Jan Baptist Vermorken, Filip Lardon, An Wouters   +10 more
doaj   +1 more source

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer [PDF]

Cancers, 2020
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor-intrinsic resistance mechanism is cross-talk between the EGFR and hepatocyte growth factor (HGF)/cMet pathways. Dual pathway inhibition may overcome cetuximab resistance.
Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile   +12 more
openaire   +4 more sources

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

Acta Biochimica et Biophysica Sinica, 2022
Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid
Hong Hi-Ju, Shao Yanfei, Zhang Sen, Yang Guang, Jia Hongtao, Yang Xiao, Huang Ling, Li Shuchun, Aikemu Batuer, Zhang Luyang, Ma Junjun, Zang Lu, Sun Jing, Zheng Minhua   +13 more
doaj   +1 more source

AXL Mediates Resistance to Cetuximab Therapy [PDF]

Cancer Research, 2014
Abstract The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non–small cell lung ...
Toni M, Brand, Mari, Iida, Andrew P, Stein, Kelsey L, Corrigan, Cara M, Braverman, Neha, Luthar, Mahmoud, Toulany, Parkash S, Gill, Ravi, Salgia, Randall J, Kimple, Deric L, Wheeler   +10 more
openaire   +2 more sources

Nuclear EGFR contributes to acquired resistance to cetuximab [PDF]

Oncogene, 2009
Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer.
C, Li, M, Iida, E F, Dunn, A J, Ghia, D L, Wheeler   +4 more
openaire   +2 more sources

Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt. [PDF]

Biomed Res Int, 2020
Introduction. Although cetuximab has been widely used in the treatment of colon cancer, a large number of patients eventually develop drug resistance. Therefore, it is essential to clarify the mechanism of drug resistance. Methods. In this study, we combined in silico analysis and a single guide RNA (sgRNA) library to locate cetuximab‐sensitive genes ...
Cai P, Xie Y, Dong M, Zhu Q.
europepmc   +4 more sources

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab [PDF]

Cancer Biology & Therapy, 2011
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to down stream activation of the PI3K/AKT, RAS/RAF/MEK/ERK and PLCγ/PKC pathways that influence cell proliferation, survival and the metastatic potential of tumor cells ...
Toni M, Brand, Mari, Iida, Deric L, Wheeler   +2 more
openaire   +2 more sources

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab. [PDF]

PLoS ONE, 2017
The EGFR-specific mAb cetuximab is one of the most effective treatments for oropharyngeal carcinoma, while patient responses to EGFR inhibitors given alone are modest.
Chaonan Sun, Chuyang Han, Yuanjun Jiang, Ning Han, Miao Zhang, Guang Li, Qiao Qiao   +6 more
doaj   +1 more source